Eric Gornstein Talaris head of new product planning

Eric Gornstein

Eric serves as the Head of New Product Planning for Talaris Therapeutics. He joined from Radius Health, where he led commercial insights and analytics efforts for the company’s portfolio of medicines in the areas of osteoporosis, oncology, and endocrine diseases. While at Radius, he helped build the commercial operations organization and infrastructure to launch their first product, TYMLOS (TM) in the United States. Previously, Eric served in roles of increasing authority in market and business development at Biogen, Millennium, TransForm, Acceleron and AstraZeneca; led strategy engagements at Leerink Partners Consulting (acquired by Navigant Consulting’s Life Sciences practice); and authored global biopharmaceutical market studies at Decision Resources. He began his career conducting pediatric genetic research at Boston Children’s Hospital. Eric has a BA with distinction in biology from Boston University, where he was a Trustee Scholar, and an MBA from MIT Sloan School of Management.